Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

EDELWEISS phase IIb study of linzagolix achieves primary and secondary endpoints

June 20, 2018

Rhythm announces new topline clinical data for setmelanotide in rare genetic disorders of obesity

June 19, 2018

Agios initiates phase III ACTIVATE study of AG-348 in pyruvate kinase deficiency

June 19, 2018

Safety run-in results presented from phase III ANDROMEDA study on daratumumab

June 19, 2018

URAT1 inhibitors identified at Atom Bioscience and Pharmaceutical

June 18, 2018

NeuroVive Pharmaceutical patents protonophores for NAFLD

June 15, 2018

Inozyme introduces genetic testing program for two rare calcification disorders

June 15, 2018

First participant dosed in phase II study of vosoritide in infants and young children

June 15, 2018

Diamyd Medical receives approval to initiate phase I/II study of Remygen

June 15, 2018

FDA awards fast track designation to RGX-111 for MPS I

June 13, 2018

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 14, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 14, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Clinical trial fraud ends with guilty pleas
BioWorld
In another real-life episode of “sponsor beware,” the owners of a clinical research facility pleaded guilty March 10 in U.S. district court to fraud charges...